Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Branebrutinib in SLE, pSS, and RA
NCT04186871Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of branebrutinib in systemic lupus erythematosus (SLE), primary Sjögren's syndrome, rheumatoid arthritis (RA), sponsored by Bristol Myers Squibb. Started Jan 2020; status: completed.
02
Drugs
branebrutinib
03
Conditions
systemic lupus erythematosus (SLE)primary Sjögren's syndromerheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04186871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04186871.